{"groups":[{"description":"etopodide, doxorubicin, cisplatin and mitotane\n\nEtoposide\n\nDoxorubicin\n\nCisplatin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (Sz-M)","id":"FG000","title":"EDP-M"},{"description":"streptozotocin and mitotane\n\nStreptozotocin\n\nMitotane\n\nparticipants who progressed during first line therapy, were eligible to the alternative treatment (EDP-M)","id":"FG001","title":"Sz-M"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"151"},{"groupId":"FG001","numSubjects":"153"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"148"},{"groupId":"FG001","numSubjects":"149"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"84"},{"groupId":"FG001","numSubjects":"101"}],"type":"Received Second Line Therapy"},{"achievements":[{"groupId":"FG000","numSubjects":"151"},{"groupId":"FG001","numSubjects":"153"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}